Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Leases (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Current Leases for 7 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 19.57% to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a 19.57% increase, with the full-year FY2025 number at $1.8 million, up 19.57% from a year prior.
  • Current Leases was $1.8 million for Q4 2025 at Kymera Therapeutics, down from $1.9 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $11.8 million in Q2 2025 to a low of $1.0 million in Q3 2023.
  • A 5-year average of $3.2 million and a median of $1.5 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: tumbled 70.05% in 2024, then soared 930.98% in 2025.
  • Kymera Therapeutics' Current Leases stood at $1.1 million in 2021, then grew by 23.73% to $1.4 million in 2022, then surged by 259.94% to $5.1 million in 2023, then crashed by 70.05% to $1.5 million in 2024, then increased by 19.57% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Current Leases are $1.8 million (Q4 2025), $1.9 million (Q3 2025), and $11.8 million (Q2 2025).